Taiwan-based clinical stage biotechnology company Formosa Pharmaceuticals (TWO:6838) announced on Thursday that it has signed a licensing deal with Medvisis Switzerland AG for clobetasol propionate ophthalmic suspension (APP13007) in Switzerland and Liechtenstein.

APP13007 treats post-surgical eye inflammation and pain.

Under the agreement Medvisis will exclusively commercialise the drug in Switzerland and Liechtenstein. The deal includes upfront payment, sales milestones and additional consideration.

Approved by the US Food and Drug Administration (FDA) in March 2024, APP13007 was launched in the United States in September.

APP13007 uses Formosa's APNT nanoparticle platform, enabling a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. Surgeon surveys highlighted rapid pain relief and low side effects as key advantages.